Results

Total Results: 1,653 records

Showing results for "described".

21. Erythropoiesis-Stimulating-Agents-Utilization Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
    February 01, 2011 - agents among Medicare beneficiaries with kidney disease Erythropoietins Data Points #4 The findings described … The work described herein was commissioned for presentation at the March 24, 2010, Medicare Evidence … These groups are more thoroughly described in the subsequent Definitions and Methodology section. … 4 Relating Timing of Practice and Policy Events to Potential Impact on ESA Use As previously described … DEFINITIONS AND METHODOLOGY Eligible Population Unless otherwise specified, the ESA utilization described

22. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-ovarian-contraceptives_research-protocol.pdf
    March 13, 2012 - This process is described further in section IV F. … The safety outcomes will be framed to help identify adverse events as described in KQ 5. … Data necessary for assessing quality and applicability, as described in the General Methods Guide,20 … These outcomes were de- prioritized following the ranking process described in Sections II and IV … These outcomes were de-prioritized following the ranking process described in Sections II and IV

23. Disposition of Comments_Technical Brief No. 49: Evidence Map on Home- and Community-Based Services and Person-Centered Care for Older Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-map-technical-brief-49-disposition-comments.pdf
    September 05, 2024 - The gaps described in Section 3.2.3 can be interpreted as the guide for future research. … Public Reviewer: Paul Kilgore, Wayne State University Regarding whether this report described both … Public Reviewer: Paul Kilgore, Wayne State University Regarding whether this report described both … Public Reviewer: Paul Kilgore, Wayne State University Regarding whether this report described both … Public Reviewer: Paul Kilgore, Wayne State University Regarding whether this report described both

24. Cer-235-Pharma-Nonpharm-Ptsd-Update-Appendix-G-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-235-pharma-nonpharm-ptsd-update-appendix-g-1.xlsx
    May 29, 2025 - Blinding methods appear adequate (e.g., double-dummy technique for drug trials) No: • Open-label • Described … drug trials) AND/OR outcome assessment is objective (e.g., labwork, blood test) No: • Open-label • Described … Blinding methods appear adequate (e.g., double-dummy technique for drug trials) No: • Open-label • Described

25. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
    February 01, 2015 - The other sets of papers are described in the sections below, including: 1. … Only two products described external peer review and in one case peer review was not always done. … , while in another three cases the searches were described as not limited or “comprehensive.” … Interviewees described several rapid review products, some completed within days (Table E- 1). … Types of Rapid Review Products Described by Key Informants

26. Template for Reports Developed (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-topic-nomination_methods.pdf
    November 01, 2012 - Data Sources: The topic nomination development processes described in this paper are derived from 4 … Results of the topic selection process are described in a Nomination Summary Document to communicate … Results of the topic selection process are described in a Nomination Summary Document (described below … above) and primary studies (described below under Feasibility Scan). … The context and purpose of each of these products is described in Table 4.

27. Disposition of Comments: CER 230 Therapies for Clinically Localized Prostate Cancer (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-230-prostate-cancer-comments.pdf
    September 17, 2020 - We described findings when available, cautioned about over interpretation of subgroups findings, and … We described policy and practice implications of our findings.

28. Registry of Patient Registries (RoPR) Policies and Procedures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/registry-of-patient-registries_research-2012-2_1.pdf
    January 01, 2012 - The policies and procedures described here support the RoPR’s goals of providing a searchable central … These are described in the next section. … As described earlier, funding organizations, both public and private, might require registration as … Such negative incentives are viewed as less likely to be enacted given the reasons described in the … Stakeholders recommended that the RoPR maintain the outreach and dissemination activities described

29. Glaucoma-Treatment Research-Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/glaucoma-treatment_research-protocol.pdf
    November 16, 2010 - These types of glaucoma may also be described in the literature as the following conditions: • … The outcomes are as described above in Outcomes for Key Questions 1 through 4, and the criteria for … inclusion/exclusion are described in Section IV-A. … The specific populations, interventions, and outcomes of interest are described in Section II. … Studies labeled “ include” will be further assessed for methodological quality as described in Section

30. Disposition of Comments for CER 204 Methods for Evaluating Natural Experiments in Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-204-obesity-disposition-comments.pdf
    December 01, 2017 - The extent to which this occurs should be assessed and described. … Reviewer #4: Clarity and Usability The limitations and future research are described. … We described how we operationalized the definition to make it clearer. … Reviewer #1: Methods The PICOTS framework was well laid out and well described. … Many of these interventions were described as multi-dimensional and had multiple targets.

31. Evidence Report on the (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-centered-medical-home_research-protocol.pdf
    February 23, 2012 - (Specific PCMH components are described in the section on PICOTS, B: Interventions, below.) … The comprehensive PCMH intervention is the combination of the components described below, not the individual … We will evaluate the quality of individual studies using the approach described in AHRQ’s General Methods … For RCTs, we will use the key criteria described in AHRQ’s General Methods Guide,25 adapted to this … We will assess applicability using methods described in the General Methods Guide.

32. Making Healthcare Safer IV: High Reliability Organization (HRO) as a Patient Safety Practice (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/hro-protocol.pdf
    January 01, 2023 - quality outcomes even in the face of complex challenges with high hazard potential.3 HRO culture can be described … The evidence brief also described metrics for measuring a health system’s progress towards becoming … HROs were highlighted as a recent trend in healthcare quality improvement and described as “organizations … maintaining high levels of safety for extended periods of time.”2 Other HRO characteristics were described … quality outcomes even in the face of complex challenges with high hazard potential.3 HRO culture can be described

33. Medical Therapies for Children With Autism Spectrum Disorder—An Updaterum Disorder--An Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-medical-disposition.pdf
    May 26, 2017 - The target population is well described and defined - however, it would be helpful to the reader if … TEP Reviewer #1 Methods Inclusion and exclusion criteria are well described and justifiable. … Literature search strategy robust and well described. Thank you for your comments. … TEP Reviewer #1 Methods The definitions of outcome measures described risk of bias assessment of … The authors clearly described limitations of the CER and evidence based.

34. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/registries-guide_executive.pdf
    April 01, 2007 - The information described in this handbook, and particularly in this chapter, is also designed to be … • The target population is described, including plans to recruit study subjects. … • A plan for quality assurance is described in the protocol. … • Completeness of information on eligible patients has been evaluated and described. … • If models are used, the specific data elements that are included are described.

35. Disposition of Comments Report for Evidence Report 215 Safety of Vaccines Used for Routine Immunization in the United States (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/vaccine-safety_disposition-comments.pdf
    January 01, 2020 - We have added references for each study design described. … Chen,1997 was described because it was not covered by the IOM report. … In general the characteristics are clearly described. … TEP # 3 Summary/ Discussion Limitations were clearly described. … Similarly, event severity was poorly described.

36. Disposition of Comments Report for The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
    September 29, 2014 - The characteristics of the studies are clearly described. … The characteristics of the studies included are clearly described. … Peer Reviewer 5 Methods Well described and executed Thank you for your comment. … The target population and intervention are clearly described and appropriate. … Limitations are adequately described. The future research section is clear.

37. Disposition of Comments Report for Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-immunotherapy-2010_disposition-comments.pdf
    January 01, 2010 - The methodology to assess the body of evidence is described in the methods section. … Instead, as described in our methods section, In our grade assignments, we considered the limitations … The methodology to assess the body of evidence is described in the methods section. … All the allergens are described very carefully in the appendices. … Several authors described the allergen as “mix .

38. Disposition of Comments: Peripheral Nerve Blocks for Postoperative Pain Management in Cardiothoracic Surgery: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-nerve-blocks-disposition-comments.pdf
    August 15, 2025 - They described the report as being “logical,” “well described,” and “easy to follow.” … As you have described, we also found many potential biases in these studies, which is one reason why … Medical Center Discussion 3) Page 69, 7.2.6: There is an anterior as well as posterior pathway described … We have described these methods in more detail. … We have added statements as described above to remind the audience of the importance of the patient

39. Dietary Saturated Fat Replacement and Plasma Lipid and Cardiovascular Events (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/saturated-fat-replacement-protocol.pdf
    January 01, 2024 - Methods The systematic review will follow the EPC Program methodology, as described in its Methods … Studies will be included in the review based on the study-specific inclusion and exclusion criteria described … Polyunsaturated fatty acids (PUFA) o Combination of the above • Dietary intake must be defined or described … comparative studies  Must account for potential confounders  Dietary intake must be defined or described … Data Synthesis Each study will be described in summary and evidence tables presenting study design

40. Emerging MRI Technologies for Imaging Musculoskeletal Disorders under Loading Stress (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-disorders-imaging_disposition-comments.pdf
    November 01, 2011 - Although this is described later under findings/other sections, the intro (and Executive Summary) leads … [sic] As described above, by the very nature the Technical Brief, a strict definition of Populations … A systematic approach for describing the limitations of the studies overall could be described. … We have described our approach for making methodological recommendations for future studies in the … Peer Reviewer 3 (Results) Findings, page 23, line 8 This needs to be described earlier.